Standout Papers

Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder 2023 2026 202465
  1. Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder (2023)
    Sean J. Pittock, Michael Barnett et al. Annals of Neurology

Immediate Impact

4 standout
Sub-graph 1 of 2

Citing Papers

Myasthenia gravis: the changing treatment landscape in the era of molecular therapies
2024 Standout
A guide to complement biology, pathology and therapeutic opportunity
2023 Standout
4 intermediate papers

Works of Marcus Yountz being referenced

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD
2021
Consistent improvement with eculizumab across muscle groups in myasthenia gravis
2020
and 3 more

Author Peers

Author Last Decade Papers Cites
Marcus Yountz 232 148 74 24 287
Clémence Boutière 174 239 76 24 326
Kerri Prain 234 95 35 16 313
Magd Zakaria 83 221 35 27 285
Seyed Mohammad Baghbanian 84 128 30 40 222
Elvira Sbragia 80 190 34 25 244
P. Adam 114 120 21 26 285
Andrew Swayne 138 98 75 19 295
Christopher LaGanke 78 188 65 28 280
Ratnakar Pingili 73 146 72 15 178
Saskia Bresch 115 88 24 21 229

All Works

Loading papers...

Rankless by CCL
2026